SEC Form 8-K Summary
Registrant: Coeptis Therapeutics Holdings, Inc. The provided metadata identifies “Z Squared Inc.,” but the filing names Coeptis Therapeutics Holdings, Inc. as the registrant.
Reporting date: January 29, 2024; filed February 1, 2024. The filing reports a Nasdaq listing deficiency and updates related risk factors.
Business Context and Reporting Period
The company’s common stock trades under the symbol COEP and its warrants under COEPW on the Nasdaq Capital Market. The company identifies itself as an emerging growth company.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, cash balance, or other operating performance figures. It states that Nasdaq continued-listing requirements include minimum stockholders’ equity of $2.5 million, but it does not disclose the company’s current equity balance or compliance status for that requirement.
Material Changes and Listing Status
- Nasdaq notified the company on January 29, 2024 that its common stock had closed below the required minimum bid price of $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- The notice had no immediate effect on the listing; the common stock remained listed on the Nasdaq Capital Market as of the filing.
- The company received an initial 180-calendar-day compliance period ending July 29, 2024.
- Compliance can be regained if the stock closes at or above $1.00 for at least 10 consecutive business days before the deadline.
- If the deficiency is not cured, Nasdaq may grant a second 180-day period if applicable market-value and other initial listing requirements are satisfied and the company notifies Nasdaq of its intent to cure.
Outlook, Risks, and Contingencies
Management stated that it will monitor the stock’s closing bid price and seek to regain compliance. There is no assurance that the company will meet the minimum bid-price requirement, receive an additional compliance period, or satisfy other Nasdaq listing requirements.
Failure to regain compliance could result in delisting, subject to the company’s right to appeal a delisting determination to a Nasdaq hearings panel. If the securities cannot be listed on another Nasdaq tier or national securities exchange, they could trade over the counter.
Potential consequences identified by the company include reduced liquidity and market quotations, penny-stock status, less analyst and news coverage, reduced investor confidence, difficulty raising capital, and fewer business-development opportunities.
Key Facts for Investors to Verify
- Whether the stock regained compliance with the $1.00 minimum bid-price requirement by July 29, 2024 or during any subsequent extension.
- Whether Nasdaq granted a second compliance period or issued a delisting determination.
- The company’s stockholders’ equity and compliance with Nasdaq’s $2.5 million minimum-equity requirement.
- Any subsequent reverse stock split, financing, capital raise, or other action intended to restore listing compliance.
- The correct issuer identity, because the request metadata names Z Squared Inc., while the filing identifies Coeptis Therapeutics Holdings, Inc.